Company Compugen Ltd. TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Products
100.0
%
| 8 | 100.0 % | 33 | 100.0 % | +346.12% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
70.1
%
| 0 | 0.0 % | 23 | 70.1 % | - |
Europe
29.9
%
| 8 | 100.0 % | 10 | 29.9 % | +33.33% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01/02/01 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01/22/01 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Zurit Levine
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/99/01 |
Yvonne Naughton
IRC | Investor Relations Contact | - | 01/21/01 |
Eran Ben-Dor
LAW | General Counsel | - | 01/19/01 |
Dorit Amitay
HRO | Human Resources Officer | 56 | 01/99/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 02/17/02 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11/18/11 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11/18/11 |
Eran Perry
BRD | Director/Board Member | - | 01/17/01 |
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01/02/01 |
Director/Board Member | 56 | 11/18/11 | |
Director/Board Member | 70 | 01/22/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 89,530,193 | 84,717,013 ( 94.62 %) | 0 | 94.62 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |